ESML's Core Assets May Indicate a 14% Profit Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 01 2025
0mins
Source: NASDAQ.COM
ETF Analysis Overview
- Implied Analyst Target Price for ESML: The iShares ESG Aware MSCI USA Small-Cap ETF (ESML) has an implied analyst target price of $50.67 per unit, based on its underlying holdings.
- Current Trading Price and Upside Potential: With ESML currently trading at approximately $44.32 per unit, analysts project a potential upside of 14.34% based on the average target prices of the ETF's holdings.
Notable Holdings with Upside Potential
- NovoCure Ltd (NVCR): Trading at $12.33 per share, NVCR has an average analyst target price of $27.19, indicating a significant upside of 120.49%.
- Arcutis Biotherapeutics Inc (ARQT): Currently priced at $15.52, ARQT has a target price of $22.62, suggesting a potential increase of 45.78%.
- fuboTV Inc (FUBO): With a recent trading price of $3.54, FUBO's average target price is $5.08, reflecting an upside of 43.79%.
Analyst Target Price Considerations
- Market Sentiment and Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, considering recent developments in the companies and their industries.
- Implications of High Price Targets: A high target price relative to a stock's current trading price may indicate optimism but could also lead to potential downgrades if the targets are based on outdated information.
Conclusion
- Investor Research Importance: The analysis emphasizes the need for further research by investors to assess the validity of analyst targets and the potential for future stock performance.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like ARQT with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on ARQT
Wall Street analysts forecast ARQT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ARQT is 30.25 USD with a low forecast of 21.00 USD and a high forecast of 37.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
7 Buy
1 Hold
0 Sell
Strong Buy
Current: 25.450
Low
21.00
Averages
30.25
High
37.00
Current: 25.450
Low
21.00
Averages
30.25
High
37.00
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company is focused on developing and commercializing treatments for dermatological diseases with high-unmet medical needs. Its portfolio is comprised of topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. Its lead product, ZORYVE, is for the treatment of plaque psoriasis, including psoriasis in the intertriginous areas, in individuals 12 years of age or older. The ZORYVE is also indicated for topical treatment of mild to moderate atopic dermatitis. ZORYVE cream is a once-daily topical formulation of roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor. The Company’s pipeline includes ARQ-255, ARQ-252, and ARQ-234. Its ARQ-255 is being developed for the treatment of alopecia areata. ARQ-252 is an alternative topical cream formulation of ivarmacitinib that the Company is developing for chronic hand eczema and vitiligo.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arcutis' ZORYVE Revenue Reaches $244.6M in 2025 YTD, Anticipates $470M for 2026
- Significant Sales Growth: Since its launch in 2022, Arcutis' ZORYVE product has seen sales reach $59.6 million in 2023 and $166.5 million in 2024, reflecting strong physician adoption and market demand, with 2025 YTD revenue hitting $244.6 million, further solidifying its market position in chronic inflammatory skin disease treatment.
- Substantial Market Potential: Arcutis anticipates net product revenue for ZORYVE to range between $455 million and $470 million in 2026, with peak sales projected to reach $2.6 billion to $3.5 billion, indicating significant growth opportunities in the dermatology market and potential to displace traditional topical corticosteroids.
- Ongoing Clinical Research: The company is conducting safety studies for ZORYVE cream 0.05% in infants aged 3 months to 24 months, with topline data expected this quarter, while also exploring ZORYVE foam 0.3% for vitiligo and hidradenitis suppurativa, expanding its indications.
- Strong Cash Position: As of September 30, 2025, Arcutis reported $191.4 million in cash and cash equivalents, ensuring sufficient funding for future R&D and market expansion, thereby enhancing its viability in the competitive biopharmaceutical landscape.
Continue Reading
Sprott Silver Miners ETF Declines 2.3% with Americas Gold and Vizsla Silver Underperforming
- ETF Performance Decline: The Sprott Silver Miners & Physical Silver ETF fell approximately 2.3% in Wednesday afternoon trading, reflecting a weak sentiment towards silver mining stocks that could impact investor confidence.
- Individual Stock Weakness: Shares of Americas Gold and Silver dropped about 2.8%, while Vizsla Silver declined by approximately 1.6%, indicating the vulnerability of these companies in the current market environment, potentially leading to capital outflows.
- Market Trend Analysis: The overall decline of the ETF is linked to fluctuations in silver prices and investor risk aversion towards mining stocks, which may influence future investment decisions and capital allocation.
- Investor Focus: As silver mining stocks continue to struggle, investors may need to reassess their allocations within precious metal portfolios to mitigate potential market risks.
Continue Reading